NAYA Biosciences Inc
NASDAQ:NAYA
Net Margin
NAYA Biosciences Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
21.9m USD |
-120%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
218.8B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175.4B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
148.4B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
141.5B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
115.9B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
66.8B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
57.9B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.5B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
291.6B CNY |
33%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37.2B USD |
10%
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on NAYA Biosciences Inc's most recent financial statements, the company has Net Margin of -119.9%.
You don't have any saved screeners yet